MetaCap

ADMA Biologics (ADMA) vs Adaptive Biotechnologies (ADPT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Adaptive Biotechnologies (ADPT) has outperformed ADMA Biologics (ADMA) over the past year, gaining 50.1% versus a loss of 23.3%. Over five years, ADMA leads with a +808.3% price change compared with -0.7% for ADPT. Adaptive Biotechnologies is the larger company by market cap ($4.52 billion vs $2.92 billion), about 1.5 times the size.

ADMA Biologics converts more of its revenue into profit, with a net margin of 28.8% versus -21.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ADMA-23.34%ADPT+50.08%
+69%+3%-62%
Nov 21, 20251 yearNov 20, 2026
ADMA+760.78%ADPT+2.12%
+1514%+673%-168%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ADMA versus ADPT key metrics
MetricADMAADPT
Share price$13.17$27.93
Market cap$2.92B$4.52B
1-day change-1.27%-0.43%
YTD return-27.80%+71.98%
1-year return-23.34%+50.08%
5-year return+808.28%-0.68%
P/E ratio (TTM)17.10—
Forward P/E14.06—
EPS (TTM)$0.77$-0.45
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$510.17M$276.98M
Revenue growth (YoY)+19.63%+54.77%
Net income (latest FY)$146.93M$-59.50M
Gross margin57.39%74.24%
Operating margin37.53%-20.62%
Net margin28.80%-21.48%
52-week high$20.46$32.21
52-week low$7.21$12.00
Distance from 52-week high-35.62%-13.29%
Analyst consensusbuystrong_buy
Avg. price target upside+36.67%+21.23%
Average volume3.23M2.20M
Shares outstanding221.85M161.88M
Employees640624
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ADPT has outperformed ADMA by 73.4 percentage points over the past year.
  • ADMA Biologics is more profitable, keeping 28.8 cents of every revenue dollar as net income versus -21.5 cents for Adaptive Biotechnologies.
  • Adaptive Biotechnologies grew revenue faster in its latest fiscal year (+54.77% vs +19.63%).

About ADMA Biologics

ADMA stock →

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 640 employees

About Adaptive Biotechnologies

ADPT stock →

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 624 employees

ADMA vs ADPT FAQ

Which is bigger, ADMA Biologics or Adaptive Biotechnologies?

Adaptive Biotechnologies (ADPT) is larger, with a market capitalization of $4.52B compared with $2.92B for ADMA Biologics (ADMA).

Which stock has performed better over the past year, ADMA or ADPT?

ADPT returned +50.08% over the past 12 months, compared with -23.34% for ADMA (price return, excluding dividends). Past performance does not predict future results.

Are ADMA Biologics and Adaptive Biotechnologies in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons